Lin Fang, Hu Shaorun, Chen Jinxiang, Li Haiyang, Li Mengting, Li Rong, Xu Min, Luo Mao
Basic Medicine Research Innovation Center for cardiometabolic diseases, Ministry of Education; Laboratory for Cardiovascular Pharmacology, Department of Pharmacology, School of Pharmacy, Southwest Medical University, Luzhou, Sichuan, China; Municipal Key Laboratory of Thrombosis and Vascular Biology, Luzhou, Sichuan, China; Department of Pharmacy, The Second People's Hospital of Yibin, Yibin, Sichuan, China.
Basic Medicine Research Innovation Center for cardiometabolic diseases, Ministry of Education; Laboratory for Cardiovascular Pharmacology, Department of Pharmacology, School of Pharmacy, Southwest Medical University, Luzhou, Sichuan, China; Department of Pharmacy, The Second People's Hospital of Yibin, Yibin, Sichuan, China.
Cytokine. 2025 Jun;190:156926. doi: 10.1016/j.cyto.2025.156926. Epub 2025 Mar 22.
Bladder cancer (BLCA) is an aggressive malignancy characterized by limited therapeutic options and a poor prognosis. Research has indicated that abnormally expressed miRNAs play a significant role in the pathogenesis of BLCA, although the specific mechanisms remain unclear. MiR-125b plays a tumor suppressor role in a variety of cancers and affects the biological processes of cancer cells such as proliferation, invasion, migration and apoptosis by regulating different signaling pathways. Elucidation of the molecular mechanisms underlying miR-125b may provide clinical therapeutic strategies for bladder cancer. Here, miR-125b was downregulated whereas its targets IL-6R and STAT3 were upregulated in BLCA, as evidenced by bioinformatics analysis. Kaplan-Meier analysis confirmed that miR-125b serves as an independent prognostic factor linked to overall survival (OS) in patients with bladder cancer. Furthermore, overexpression of miR-125b significantly inhibited BLCA cell proliferation, migration, and invasion, while promoting apoptosis, as evidenced by an increased Bax/Bcl-2 ratio and activated cleaved caspase-3. Further investigations demonstrated that miR-125b directly targets and downregulates both IL-6R and STAT3. In a xenograft model, miR-125b overexpression effectively inhibited tumor growth in bladder cancer by blocking IL-6/IL-6R and STAT3 signaling pathways. Collectively, these findings broaden our understanding of the mechanism by which miR-125b acting as a BLCA suppressor in apoptotic regulation by targeting the IL-6/IL-6R/STAT3 signaling pathway, providing novel insights regarding the design of novel miRNA based therapeutic strategies against BLCA.
膀胱癌(BLCA)是一种侵袭性恶性肿瘤,其特征在于治疗选择有限且预后不良。研究表明,异常表达的微小RNA(miRNA)在膀胱癌的发病机制中起重要作用,尽管具体机制尚不清楚。MiR-125b在多种癌症中发挥肿瘤抑制作用,并通过调节不同的信号通路影响癌细胞的增殖、侵袭、迁移和凋亡等生物学过程。阐明miR-125b的分子机制可能为膀胱癌提供临床治疗策略。在这里,生物信息学分析表明,在膀胱癌中miR-125b表达下调,而其靶标白细胞介素6受体(IL-6R)和信号转导和转录激活因子3(STAT3)表达上调。Kaplan-Meier分析证实,miR-125b是膀胱癌患者总生存期(OS)的独立预后因素。此外,miR-125b过表达显著抑制膀胱癌细胞的增殖、迁移和侵袭,并促进细胞凋亡,Bax/Bcl-2比值增加和裂解的半胱天冬酶-3激活证明了这一点。进一步研究表明,miR-1直接靶向并下调IL-6R和STAT3。在异种移植模型中,miR-125b过表达通过阻断IL-6/IL-6R和STAT3信号通路有效抑制膀胱癌肿瘤生长。总的来说,这些发现拓宽了我们对miR-125b通过靶向IL-6/IL-6R/STAT3信号通路在凋亡调节中作为膀胱癌抑制因子的机制的理解,为设计基于新型miRNA的膀胱癌治疗策略提供了新的见解。